| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01970527 Details | 2020-02-13 Interventional | 2 | 23 | Ipilimumab Melanoma Recurrent Melan… Stage IV Skin M… | Change in standard of care We stopped this trial early as the standard of care shifted during the course of the study. Participant flow, Baseline Characteristics and Adverse events were recorded as appropriate for the 23 patients (22 evaluable) who consented to the trial. | |||
| NCT02225574 Details | 2020-02-12 Interventional | 1 | 1 | Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… | Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II - | |||
| NCT01238224 2007-003921-25 Details | 2020-02-12 Interventional | 1 | 22 | Tadalafil Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes | Durability of study medications could not be guaranteed after the expire date. - | |||
| NCT02867280 Details | 2020-02-11 Interventional | 3 | 154 | Sorafenib Carcinoma Carcinoma, Hepa… Recurrence Hepatocellular … | Midterm analysis showed negative results. - | |||
| NCT02442492 Details | 2020-02-11 Interventional | 2/3 | 21 | Sildenafil Citr… Fetal Growth Re… Fetal Growth Re… Intrauterine Gr… | Trial terminated following Dutch DSMB recommendation for their Study - | |||
| NCT01917318 Details | 2020-02-11 Interventional | 2 | 1 | Iloperidone Stress Disorder… Stress Disorder… Post Traumatic … | Enrollment challenges - Single participant discontinued after placebo, no relevant outcome
measure data was recorded. - | |||
| NCT03828929 Details | 2020-02-10 Interventional | 3 | 3 | Thiamine Shock Shock, Septic Septic Shock | Recent similar studies have been completed and published showing no benefit to the
intervention. - | |||
| NCT03267940 Details | 2020-02-07 Interventional | 1 | 85 | Atezolizumab Adenocarcinoma Cholangiocarcin… Cholangiocarcin… Cholangiocarcin… Cholangiocarcin… Gallbladder Ade… | Sponsor decision The study was terminated prematurely by the Sponsor due to stopping the clinical development of PEGPH20 in all indications based on negative pivotal data in metastatic pancreatic cancer. | |||
| NCT04259684 Details | 2020-02-06 Interventional | 2/3 | 0 | Nitric Oxide Acute Kidney In… Heart Defects, … Heart Diseases Wounds and Inju… Congenital Hear… | revised and combined with another protocol - | |||
| NCT04254380 Details | 2020-02-05 Interventional | 3 | 0 | Insulin Lispro Diabetes Mellit… Diabetes Mellit… | GanLee cancelled study -FDA Draft Guidance: "Clinical Immunogenicity Considerations for
Biosimilar & Interchangeable Insulin Products" released 11/25/2019 - | |||
| NCT04043845 Details | 2020-02-05 Interventional | 1 | 0 | Ibrutinib Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, Mantl… Waldenstrom Mac… Chronic Lymphoc… Mantle Cell Lym… Marginal Zone L… | Business development reasons. - | |||
| NCT03633526 2018-001711-67 Details | 2020-02-05 Interventional | 3 | 18 | Ivacaftor VX-659 Cystic Fibrosis Fibrosis | Study discontinued after Part A due to Sponsor's discretion. The study was terminated before start of Part B due to sponsor discretion. | |||
| NCT02117349 Details | 2020-02-05 Interventional | 2 | 55 | Fibrin Tissue A… Gelatin Sponge,… Hemorrhage Surgical Bleedi… | Non-safety device related issues - | |||
| NCT02117024 Details | 2020-02-05 Interventional | 2 | 66 | Cyclophosphamid… Docetaxel Erlotinib Hydro… Gemcitabine Paclitaxel Pemetrexed Vinorelbine Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Sponsor Decision; strategic - based on changing treatment landscape Study was discontinued prematurely (50% enrollment) by the Sponsor on 01 September 2015 due to changing treatment landscape (PD-1 approvals), and a subsequent change in development focus to IO combinations. See NCT02439450. | |||
| NCT04134468 Details | 2020-01-31 Interventional | 2 | 0 | Albumin-Bound P… Gemcitabine Adenocarcinoma Pancreatic Duct… | Halozyme halted development of PEGPH20 following Phase 3 failure. - | |||
| NCT02895035 Details | 2020-01-31 Interventional | 4 | 59 | Epinephrine Ketorolac Oxymetazoline Phenylephrine Cataract | Data analysis was never performed by sub-investigator small sample size some patients received pre-operative topical NSAID in both eyes, while others did not | |||
| NCT03026088 Details | 2020-01-29 Interventional | 4 | 20 | Bisoprolol Heart Failure | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which
led barrier to the recruitments. The study was terminated early due to limited beta-blocker naive participants among newly diagnosed heart failure participants. | |||
| NCT02800889 Details | 2020-01-29 Interventional | 1 | 0 | Pixantrone Lymphoma Solid Tumor (Ex… | Study withdrawn; no participants enrolled - | |||
| NCT02782052 2014-002590-10 Details | 2020-01-29 Interventional | 3 | 0 | Albuterol Bromides Ipratropium Dyspnea Familial Primar… Hypertension Pulmonary Arter… | Sponsor's decision - | |||
| NCT02743975 Details | 2020-01-28 Interventional | 1/2 | 10 | Bevacizumab Adenocarcinoma Pancreatic Aden… Pancreatic Canc… | Insufficient tumor-to-background ratios in the first three dose groups - |